Chronic myeloid leukemia: successful therapy with nilotinib in a young patient with high Sokal risk and in sub-optimal response with imatinib

Here we describe a case of a young patient with chronic myeloid leukemia, at high-risk according to the Sokal index, who started imatinib at standard dose and obtained a sub-optimal response at 12 months. This condition was not automatically an indication to change therapy, but considering the patie...

Full description

Bibliographic Details
Main Author: Fausto Palmieri
Format: Article
Language:English
Published: SEEd 2015-10-01
Series:Clinical Management Issues
Subjects:
Online Access:https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1098